Intramuscular (i.m.) injection of plasmids followed by electro-
Introduction
Gene transfer into skeletal myofibers is a rapidly evolving and potentially valuable approach in the treatment of myopathies and diseases that can be treated with systemically delivered proteins. Easy access, large mass and the ability to express, process and secrete proteins into circulation are desirable attributes that allow skeletal muscle to function as an artificial endocrine organ. 1 The selection of an optimized delivery system to enable the most efficient transfer and expression of the therapeutic gene in the myofibers is critical for the development of a robust muscle platform.
Direct injection of plasmid in saline into skeletal muscle of rodents and primates has produced transgene expression levels which were generally low and highly variable. [2] [3] [4] [5] [6] To improve the efficacy and reproducibility of plasmid delivery, protective, interactive, non-condensing (PINC) polymers 7 and non-ionic block co-polymers, consisting of ethylene oxide and propylene oxide monomers, 8 have been developed. Both systems have increased distribution of DNA within the muscle tissue and augmented transgene expression up to 10-fold compared with DNA in saline. 7, 8 However, the expression levels of certain systemic proteins following i.m. delivery with formulated plasmids were still not sufficient in animals to permit their use in the treatment of many diseases. For specific applications, a delivery technique that yields higher and more persistent levels of expression is required. Electroporation, a commonly used technique to introduce DNA and other chemical compounds into bacterial, plant and animal cell cultures, has also been used successfully in delivering plasmids into tumors, [9] [10] [11] [12] skin, 13, 14 liver 15, 16 and skeletal muscle 6, [17] [18] [19] in animals. When an i.m. injection of a plasmid suspension is followed by an application of optimized electric pulses to tissues of rodents and rabbits, transgene expression is improved by two to three orders of magnitude, as compared to i.m. injection only. 6, 17, [19] [20] [21] Recently, this procedure has been used to produce therapeutic levels of systemic erythropoietin (EPO) in rodents [20] [21] [22] and Factor IX in mice and dogs. 23, 24 Plasmids can be formulated to improve plasmid delivery by the combination of i.m. injection and EP. In addition to enhancing the levels of transgene expression, the number of injection sites and the plasmid dose required to attain a certain level of expression can be reduced. A lower plasmid dose may also minimize any inflammatory stimuli that may be associated with plasmid delivery by EP. Consequently, treatment tolerability may be improved, providing higher and more persistent gene expression from muscle.
The objective of this study was to develop a formulation that improved the efficiency of plasmid delivery by intramuscular injection in combination with electroporation, when compared to unformulated plasmid in saline. In rodents, we showed that the anionic polymer, sodium poly-L-glutamate, enhanced expression of the reporter gene SEAP up to eight-fold after i.m. injection and EP, when compared to the plasmid in saline. Circulating SEAP levels attained at the peak of expression were at least 750-fold higher than those achieved with unformulated plasmid and no electroporation. Quantitative PCR analysis of DNA extracted from muscles at various time points showed that the amount of plasmid retained was approximately three-fold higher for plasmid formulated with poly-L-glutamate than plasmid in saline after electroporation-mediated DNA delivery.
Results

Addition of empty plasmid increased reporter gene expression
To increase transgene expression after DNA delivery to skeletal muscle, the most straightforward approach is to introduce more plasmid into the tissue. Various amounts of an expression plasmid for human placental secreted alkaline phosphatase (SEAP) was injected intramuscularly into the tibialis cranialis of mice and followed by EP of the lower hind limb. Peak levels of serum SEAP were measured seven days after transfection and found to be elevated in a plasmid dose-dependent manner ( Figure  1a ). Linear regression analysis (R = 0.996) showed that in the range of plasmid dose examined (0.15 g to 25 g per animal), transgene expression as measured by serum SEAP levels was linearly proportional to the amount of plasmid injected.
High DNA doses can trigger adverse events potentially associated with immunological stimulation by plasmid DNA. 25, 26 Therefore, the optimal delivery system to introduce plasmid into skeletal muscle would ideally allow substantial levels of transgene expression with a minimal amount of DNA administered. In our search for such systems, the effect of excess plasmid mass 27 was assessed to determine if the presence of a 'silent' DNA could increase transgene expression. Various proportions of a control plasmid devoid of reporter gene (empty plasmid) and a constant dose of SEAP DNA were injected into mouse tibialis cranialis muscles. Serum levels of SEAP were measured after injection and electroporation.
For the two doses of SEAP plasmid tested (2.5 g and 15 g respectively), the peak serum concentration of the secreted protein at day 7 was significantly increased 1.5-to two-fold (P Ͻ 0.05) when the empty plasmid was coadministered with the SEAP plasmid at a two-fold weight excess (Figure 1b and c) . The amount of serum SEAP expressed from the co-injection of 2.5 g SEAP plasmid and 5.0 g empty plasmid was similar to the level observed when 6.25 g SEAP plasmid was injected alone (Figure 1a and b) . Thus, less SEAP plasmid was required when an excess amount of empty plasmid was included. In contrast, increasing the amount of empty plasmid to a six, 30 or 120-fold excess of 2.5 g per animal yielded a stepwise decrease in SEAP expression (Figure 1b) . Similarly, addition of six-and 30-fold excess of empty plasmid to 15 g of DNA abolished the positive effects on SEAP expression (Figure 1c) . 
Poly-L-glutamate enhanced SEAP expression in mouse tibialis cranialis at a low plasmid dose
The enhancement of transgene expression by adding empty plasmid illustrated that negatively charged polymers such as DNA could improve the expression of genes delivered by i.m. injection and electroporation. We proceeded to explore the possibility that other anionic macromolecules could enhance expression to levels similar to that attained with an excess of empty plasmid. Anionic polymers of different sources, molecular weights, conformational propensities and charge densities, including polypeptides, synthetic polymers and polysaccharides, were screened for their ability to enhance peak SEAP expression at 7 days (data not shown). Among all the polymers tested, the sodium salt of the anionic polypeptide poly-L-glutamic acid (poly-Lglutamate) exhibited the highest and most consistent improvement in SEAP expression. Figure 2 shows the effects of poly-L-glutamate of three different molecular weights on SEAP levels at 2.5 g plasmid/animal. The highest circulating levels of SEAP at day 7 were achieved when plasmid was formulated with either 15 mg/ml of 3-15 kDa poly-L-glutamate and 6 mg/ml of 15-50 kDa poly-L-glutamate. These SEAP levels were eight-fold higher than that for the saline con- trol and at least 750-fold higher than that attained with naked DNA injection with no electroporation. Compared to plasmid in saline, poly-L-glutamate yielded significant (P Ͻ 0.05) increases in serum SEAP levels for most conditions tested. These SEAP levels were not statistically different among the concentrations and molecular weights of poly-L-glutamate used. However, for plasmid formulated with 2 mg/ml of 3-15 kDa and 15 mg/ml of 50-100 kDa, the SEAP levels were not statistically different from plasmid in saline ( Figure 2 ).
The monomer L-glutamate was also investigated for its ability to enhance the transgene expression. Addition of L-glutamate at 0.3-15.0 mg/ml to 2.5 g SEAP plasmid per animal yielded similar serum levels of SEAP as compared to plasmid in saline (data not shown), demonstrating that a polyanion is required to enhance transgene expression.
Poly-L-glutamate enhanced SEAP expression in mouse tibialis cranialis at a high plasmid dose
As shown in Figure 1 , transgene expression was linearly proportional to plasmid dose in the range of 0.15 to 25 g plasmid per animal. Further increases in plasmid dose to 75 and 150 g of plasmid/animal yielded SEAP levels that were statistically different (P Ͻ 0.05) from that at 25 g of plasmid/animal (Figure 3a) . However, the SEAP levels were not significantly different between these two higher plasmid doses used, suggesting there was a saturation of expression such that further increases in plasmid concentrations could not improve SEAP levels.
The ability of poly-L-glutamate to enhance transgene expression at 25, 75 and 150 g plasmid/animal was investigated ( Figure 3 ). These plasmid doses were 10-, 30-and 60-fold higher than those described in Figure 2 . As previously shown in Figure 3a , similar amounts of SEAP were produced when each animal received either 75 or 150 g of plasmid in saline. The muscles may have reached the maximum capacity to express a transgene. Therefore, poly-L-glutamate was not expected to show improvement at plasmid doses of 75-150 g per animal.
Gene Therapy At 25 g plasmid per animal, poly-L-glutamate significantly (P Ͻ 0.05) increased serum SEAP levels by approximately two-fold over the saline control group for most conditions tested, except for 2 mg/ml of 3-15 kDa and 15 mg/ml of 50-100 kDa (Figure 3b ). At 75 and 150 g plasmid per animal, formulations with 15-50 kDa poly-L-glutamate at 2, 6 and 15 mg/ml also significantly (P Ͻ 0.05) increased serum SEAP levels by two-fold (data not shown). At 25 and 75 g plasmid/animal, further increase of 15-50 kDa poly-L-glutamate to 30 mg/ml did not enhance SEAP levels (data not shown). At the higher plasmid dose, the fold increase was substantially reduced compared to the eight-fold increase when 2.5 g of DNA was used (Figure 2) . Nevertheless, poly-L-glutamate (15-50 kDa) was able to increase transgene expression beyond the saturation levels observed with plasmid in saline.
Poly-L-glutamate enhanced SEAP expression in mouse gastrocnemius muscle
To explore the possibility that different muscles have a variable response to poly-L-glutamate-plasmid formulations, the injection/electroporation procedure was conducted in the gastrocnemius muscles rather than in the tibialis cranialis of CD-1 mice. When three concentrations of plasmid (30, 100 and 300 g per animal) were formulated in saline alone, transgene expression appeared to reach a plateau at the higher two doses (100 and 300 g/animal) where the SEAP levels were not statistically different (Figure 4a) . Moreover, the ability of the muscle to express SEAP is approximately 10-fold less in gastrocnemius compared to the tibialis cranialis at the 25-30 g plasmid per animal dose range. At 25 g of DNA per animal, the tibialis muscle generated more than 2000 ng/ml of serum SEAP in the absence of poly-L-glutamate (Figure 3a) whereas the gastrocnemius only expressed approximately 200 ng/ml SEAP after 30 g of plasmid in saline was injected (Figure 4a ). At the higher plasmid dose range of 75 to 300 g per animal, the decrease was only three-to five-fold. It has been previously noted that transgene expression is approximately between one and 20 times higher in the tibialis than that in the gastrocnemius. 6, 24 At 30 g plasmid per animal, poly-L-glutamate significantly (P Ͻ 0.05) enhanced SEAP expression in gastrocnemius by 7.5-fold compared to the saline control group, except for formulations of 2 and 6 mg/ml of 3-15 kDa and 2 mg/ml of 15-50 kDa (Figure 4b ). The effects of poly-L-glutamate on transgene expression at the concentrations used in Figure 4b were also examined at 100 and 300 g plasmid per animal. At 100 g plasmid per animal, 3-15 kDa and 15-50 kDa poly-L-glutamate at 6 and 15 mg/ml significantly (P Ͻ 0.05) increased SEAP levels. At 50-100 kDa, 2 and 6 mg/ml of the polymer attained similar transgene expression as the lower molecular weights (data not shown). These elevated SEAP levels were significantly higher (P Ͻ 0.05) than those attained by 300 g of plasmid per animal prepared in saline. Similar to the tibialis, poly-L-glutamate was able to surpass the saturation levels of transgene expression in the gastrocnemius. Poly-L-glutamate did not increase SEAP levels at 300 g of plasmid per animal (data not shown).
Poly-L-glutamate enhanced expression of a therapeutic gene in mice
To determine if the beneficial effects of poly-L-glutamate were gene specific, a mouse erythropoietin (mEPO) gene was introduced by i.m. injection and EP into C57BL/6 mice. The circulating EPO protein levels were compared between animals that received DNA in saline and those that received plasmid in 6 mg/ml of 15-50 kDa poly-Lglutamate. Although statistical analyses demonstrated that, for most of the concentrations and molecular weights of poly-L-glutamate tested, the enhancement in transgene expression was similar, 6 mg/ml of 15-50 kDa was chosen since this concentration and molecular weight consistently exhibited maximum levels of SEAP expression in both tibialis and gastrocnemius muscles (Figures 3 and 4) .
The plasmid formulation (75 g plasmid per animal) was injected into both tibialis cranialis and gastrocnemius muscles of C57BL/6 mice, followed by EP. Use of the mouse EPO gene avoided immune responses due to expression of a foreign gene. The expression of the mouse EPO protein was maintained throughout the experiment (Figure 5a) . At all the time points examined, the level of serum EPO for the poly-L-glutamate group was four-to 12-fold higher than that for the saline group (Figure 5a ). This difference was statistically significant (P Ͻ 0.05) except for day 70 where there was greater mouse-tomouse variability of EPO protein levels.
In the same experiment, additional mice in both the saline and poly-L-glutamate groups were treated and sacrificed on days 8, 28 and 97 to determine the amount of plasmid retained in the tibialis and gastrocnemius muscles. During the course of the study, the mice which received plasmid formulated in poly-L-glutamate exhibited a six-fold decrease in EPO plasmid in the muscles, whereas the mice in the saline group suffered a 14-fold loss in muscle EPO plasmid (Figure 5b ). At each of the three time points examined, the amount of plasmid retained in the muscle by the poly-L-glutamate group was significantly (P Ͻ 0.05) higher than that retained by the saline group by three-to seven-fold. Although the mechanism by which poly-L-glutamate enhances transgene expression is not known, it is possible that one effect of the polymer is to increase the retention of transcriptionally active plasmid in the muscles, thereby improving transgene expression and enhancing circulating levels of EPO protein.
To determine if poly-L-glutamate poses a health hazard when combined with plasmid, a preliminary safety/ toxicity study was performed in Fisher rats with i.m.
Figure 5 The effects of poly-L-glutamate on the expression and retention of mouse EPO (mEPO) gene in mice. (a) CMV-mEPO (0.5 mg/ml, 75 g/animal, 150 l total volume) formulated in either saline (open circle) or poly-L-glutamate (closed circle) (6 mg/ml, 15-50 kDa) was injected in the tibialis cranialis and gastrocnemius of C57BL/ 6 mice and the muscle tissues were electroporated. Serum concentrations of mEPO (mU/ml) were measured at the indicated time points. Values are means ± s.e.m. with n = 5 in each experimental group. (b) The tibialis cranialis and gastrocnemius muscles in mice transfected with CMV-mEPO plasmid formulated either in saline or poly-L-glutamate were isolated at days 8, 28 and 97. The amount of mEPO plasmid (ng/animal) in each animal was determined as described in Materials and methods. Values are means ± s.e.m. with n = 5 in each experimental group. There was a significant difference between the treatment groups that received plasmid in saline and that received plasmid formulated in poly-L-glutamate (P Ͻ 0.05).
injection of poly-L-glutamate alone or in combination with a human FIX plasmid and electroporation. The concentrations of poly-L-glutamate ranged from 6 mg/ml to 200 mg/ml. All animals survived during the 28-day study. Histological analyses showed reversible lesions at the site of injection that were associated with the electroporation procedure. Blood chemistry analyses revealed that hematological parameters did not deviate from the normal range for the species. Therefore, we believe that poly-L-glutamate did not pose major health risks in the animals tested.
Poly-L-glutamate enhanced expression occurs in myofibers
Plasmids for CMV-GFP or CMV-hEPO were formulated in poly-L-glutamate and delivered to the tibialis muscles of mice by i.m. injection followed by EP. GFP expression on day 4 and hEPO expression on day 6 was detected in myofibers and no evidence for expression in other cell types was detected ( Figure 6 ).
Discussion
In this study, we report that poly-L-glutamate increased transgene expression in mice after i.m. injection of plasmid followed by EP with caliper electrodes. Poly-L-gluta- mate reduces the amount of plasmid required to achieve a given level of expression over a wide range of plasmid doses. Recently, poly-L-glutamate-formulated human Factor IX gene was delivered into dogs using needle electrodes to establish therapeutically significant serum levels of the protein. 24 Therefore, poly-L-glutamate has been able to elevate the levels of secreted gene products in multiple in-vivo models.
It has been reported previously that transgene expression after plasmid delivery to skeletal muscle was a saturable process. 28, 29 We confirmed this observation using two different muscle groups in mice. In both tibialis and gastrocnemius, a plateau in reporter gene expression where further increases in plasmid dose did not elevate levels of the gene product are evident after i.m. injection of plasmid in saline followed by EP ( Figures  3 and 4) . Poly-L-glutamate exhibited greater fold-increase in transgene expression at low plasmid doses than at higher plasmid doses. Nevertheless, the polymer was able to elevate expressed protein levels exceeding the 'saturation levels' at both low and high plasmid doses (Figures 3 and 4) .
Poly-L-glutamate enhances transgene expression partly by increasing the amount of exogenous DNA present in muscle cells as evidenced by our DNA retention study. Animals receiving plasmid formulated with poly-L-glutamate maintained a higher amount of EPO DNA at all time points examined, up to 97 days when compared to the saline control group (Figure 5b) . In order to improve retention of transcriptionally active exogenous plasmid inside the nuclei of myocytes, poly-L-glutamate may augment intracellular uptake and trafficking of plasmid and/ or reduce degradation.
After direct injection into the muscle fibers, plasmid is initially distributed in the interstitial fluid and preferentially saturates low affinity positively charged binding sites on cell surfaces and extracellular matrices. Upon EP, transient aqueous pores in the plasma membrane are formed. The molecular details of plasmid movement across an electroporated plasma membrane are not known. Plasmids can either translocate into the cell interior through the aqueous pores, propelled by the change in gradient present during the electric pulses 30, 31 or complete its translocation once the pulses have ended. 30, 32 The presence of DNA endonucleases in muscle degraded 99% of unformulated plasmid within 90 min of delivery. 25 During plasmid delivery via EP, poly-L-glutamate may enhance plasmid uptake by neutralizing processes that normally deactivates exogenous DNA, such as degradation by nucleases or the binding to cationic entities in interstitial fluid. It is interesting to note that plasmid formulated with poly-L-glutamate showed similar levels of transgene expression as plasmid in saline when EP was omitted after i.m. injection (data not shown). It is possible that without the aqueous pores created by EP, poly-Lglutamate failed to protect plasmid during delivery.
Once inside the muscle cell, the plasmid is then transported to the nucleus where it is transcribed. It should be noted that plasmid sequences amplified by PCR do not necessarily represent either intact or transcriptionally active plasmids inside the nucleus. However, it is reasonable to assume that the amount of transcriptionally active plasmid retained in the nucleus is greater with poly-Lglutamate in the formulation than with saline. Poly-Lglutamate inhibits microtubule assembly by interacting with microtubule assembly protein. 33 The transport of exogenous plasmid to lysosomes where degradation occurs is reported to depend on cytoskeletal support. 34 It is possible that poly-L-glutamate prevents plasmid delivery to the lysosomes by the disruption of microtubule assembly, thereby increasing the amount of plasmid that enters the nucleus. Once in the nucleus, through its interaction with nuclear proteins such as histones, 35, 36 poly-L-glutamate may enhance the stability and subsequently retention of DNA in the nucleus.
In addition to poly-L-glutamate, empty plasmid also enhanced transgene expression under specific experimental conditions, although empty plasmid was less effective than poly-L-glutamate in terms of the magnitude of improvement in levels of secreted gene products (Figure 1 ). Other anionic polymers including dextran sulfate, pectin, poly-acrylic acid and poly-L-aspartate were also tested for their ability to enhance SEAP expression. Poly-L-aspartate and poly-acrylic acid also increased transgene expression and may be useful in some contexts. However, in our laboratory, poly-L-glutamate was more consistent in increasing transgene expression than these polymers (data not shown). The fact that the L-glutamate monomer was unable to increase the level of secreted gene products is consistent with the concept that polymeric forms are necessary to enhance transgene expression. Other characteristics including charge density, conformation propensities, molecular weight, affinity for nuclear proteins, metabolism, receptor interactions, etc. may also determine the kind and extent of their action.
Poly-(L-glutamyl) groups occurs naturally as attachments to side chains in proteins. 37 Poly-L-glutamate has been synthesized by covalently linking the ␣-amino and ␣-carboxyl terminals of L-glutamic monomer. 38 The polymer has been investigated as a conjugate to anti-cancer drugs to increase stability [39] [40] [41] and as a glue to close wounds and stop bleeding during tissue repair. 42, 43 Poly-L-glutamate did not readily produce antibodies after i.m. injection into several species of animals including human. 44 Toxicity toward poly-L-glutamate-formulated plasmid is not expected.
In summary, we have developed a unique formulation to deliver plasmid into skeletal muscle using i.m. injection in conjunction with EP. Poly-L-glutamate enhanced transgene expression compared to saline in mice using several transgenes at various plasmid doses and in two different muscle groups. Improvements in transgene expression exerted by the anionic polymer may be explained partly by its ability to increase the amount of exogenous DNA retained in the skeletal muscle. Since poly-L-glutamate is only effective in conjunction with EP, the polymer is the first formulation specifically intended to enhance delivery and expression in gene therapy protocols involving EP.
Materials and Methods
Plasmid construction and preparation All plasmids were prepared by inserting the coding region of the gene of interest into a Valentis plasmid backbone, which included a 107 bp 5' UTR, a 117 bp synthetic intron, the human growth hormone polyadenylation signal, a pUC12 origin of replication and a kanamycin resistance gene. 45 Transcription of human secreted placental alkaline phosphatase (SEAP), green fluorescent protein (GFP), mouse erythropoietin (mEPO) or human erythropoietin (hEPO) genes were driven by the CMV enhancer/promoter. The 'empty plasmid' was devoid of a coding sequence capable of expression in mammalian cells. Plasmids were grown in Escherichia coli DH5␣ and were purified using a proprietary method consisting of alkaline lysis and chromographic methods. 45 Plasmids were either administered alone in isotonic saline (150 mM NaCl) or mixed with the sodium salt of poly-L-glutamate of various molecular weights (3-15, 15-50 and 50-100 kDa) before adjusting the NaCl concentration to 150 mM with a 5 M stock. The polypeptides were purchased from Sigma (St Louis, MO, USA).
Experimental animals
Male CD-1 mice (29-31 g) and female C57BL/6 mice (18-20 g) were obtained from Charles Rivers Laboratories, Raleigh, NC, USA. The rodents were maintained in HEPA-filtered cages at a 12-h light-dark cycle at 23°C and 40% humidity in accordance with state and federal guidelines.
Injection and electroporation
Mice were anesthetized intraperitoneally with a combination anesthesia (ketamine, 74 mg/ml; xylazine, 3.7 mg/ml and acepromazine, 0.73 mg/ml) at a dose of 1.8-2.0 ml/kg before plasmid administration and muscle electroporation. For SEAP expression, plasmid formulations were administered in CD-1 mice by longitudinal injections in either the tibialis cranialis or gastrocnemius of both legs. The injection volume was 25 l for each tibialis cranialis and 50 l for each gastrocnemius. For mEPO expression in C57BL/6 mice, the animals were injected in the tibialias cranialis and gastrocnemius of both legs.
The mouse hind limb muscles were electroporated with caliper electrodes consisting of two stainless steel parallel plates (1.5 cm 2 ). Two minutes after the plasmid injection, an electric field was delivered at a voltage of 375 V/ cm by an Electro Square Porator (Genetronics, San Diego, CA, USA) in the form of two square wave pulses of 25 ms each. Animals were monitored continually after the procedure until they recovered full mobility, approximately 30-60 min from the onset of anesthesia. There were no ill effects of the electroporation procedure.
Blood collection and serum analysis
Blood samples were collected at the appropriate time points following plasmid administration and EP by the retro-orbital plexus. Approximately 250 l of blood was collected into EDTA microtainer tubes (Becton Dickinson, Franklin Lakes, NJ, USA) and centrifuged at 7000 r.p.m. for 5 min. SEAP serum levels were determined using a commercially available chemiluminescence assay (Tropix, Bedford, MA, USA) using the manufacturer's instructions. Serum levels of mouse EPO were measured with a human EPO ELISA kit (R and D Systems, Minneapolis, MN) that cross-reacts with mouse EPO, but with a five-fold reduction in sensitivity.
Isolation of total DNA and quantitative PCR analysis
To isolate total DNA from mouse tibialis cranialis and gastrocnemius muscles, each muscle sample was first homogenized in TEN buffer (10 mM Tris-HCl, pH 8, 25 mM EDTA, 100 mM NaCl) by bead beating using a MiniBead Beater 8 (BioSpec Products, Bartlesville, OK, USA) and 2.5 mm zircon/silica beads (BioSpec Products) in a screw-cap tube. A portion of the volume of each homogenate was digested overnight at 50°C in TEN buffer containing 0.5% SDS and 0.1 mg/ml proteinase K (Roche Molecular Biochemicals, Indianapolis, IN, USA). A portion of the proteinase K digest was phenol-extracted, ethanol-precipitated, washed and resuspended in TE buffer (10 mM Tris-HCl, pH 8, 1 mM EDTA). DNA concentrations were determined by measuring UV absorbance at 260 nm.
The TaqMan quantitative polymerase chain reaction (PCR) system (PE Biosystems, Foster City, CA, USA) was used to determine the amount of mouse EPO plasmid in the muscle samples. PCR assays were performed in a 96 well format in an ABI PRISM 7700 sequence detector system (PE Biosystems). Primers were acquired from SigmaGenosys (The Woodlands, TX, USA). All other reagents were acquired from PE Biosystems (Foster City, CA, USA). To detect the presence of the mouse EPO plasmid, a 5' primer and fluorogenic probe that anneal within the 5' untranslated region and a 3' primer the anneals within the mouse EPO coding region were used. Each assay included a standard curve consisting of known quantities of plasmid spiked into a background of mouse liver DNA. The standard curve ranged from 0.00001 pg (~two copies) to 1000 pg (~100 million copies) of plasmid. Each unknown muscle DNA sample was assayed in duplicate and the amount of mouse EPO plasmid was determined by comparison to the standard curve. The quantity of plasmid in all the injected muscles of each mouse was combined and considered to be the total amount of plasmid retained per animal.
Histology
Detection of green fluorescent protein (GFP) expression:
Mouse tibialis muscles were fixed in 10% neutral buffGene Therapy ered formalin, processed to paraffin and 3 m sections were made. Sections were deparaffininzed with three changes of xylene, hydrated to water and coverslipped with Vectashield with Dapi (Vector Laboratories, Burlingame, CA, USA). Fluorescent microscopy was performed with an Olympus BX-60 microscope (Olympus America, Melville, NY, USA) equipped with a SPOT digital camera (Diagnostic Instruments, Sterling Heights, MD, USA).
Human erythropoietin (hEPO) immunohistochemistry:
Mouse tibialis muscles were fixed in 10% neutral buffered formalin and processed to paraffin. 3 m sections were made and stained for hEPO immunoperoxidase. Sections were deparaffinized in three changes of xylene, followed by three changes of 100% ethanol. Sections were treated for endogenous peroxidase with methanol/hydrogen peroxide for 15 min, rinsed in distilled water, washed three times in PBS and blocked in 20% normal goat serum. Sections were then incubated for 1 h with an affinity-purified rabbit anti-EPO (hu/ms/rat) antibody (Research Diagnostics) that was diluted 1:100 in PBS/1%BSA. After three rinses with PBS, the secondary antibody (biotinylated goat anti-rabbit IgG (Vector Laboratories) diluted 1:400 in PBS, was applied for 1 h. After three rinses with PBS, Elite ABC reagent (Vector Laboratories) was applied at a dilution of 1:80 for 1 h and then rinsed with PBS. Sections were incubated in a DAB solution (Vector Laboratories) for 5 min to visualize EPO, rinsed with distilled water, counterstained with Mayer's hematoxylin, dehydrated in ethanol and coverslipped. All incubation steps were at room temperature. Microscopy was performed with an Olympus BX-40 microscope equipped with a DXC-960MD color video camera (Sony, Japan).
Statistics
One-Way ANOVA analysis using the Bonnferonni post hoc test was used to test statistical differences between experimental groups (SPPS Base 9.0, Chicago, IL, USA). P values Ͻ0.05 were considered significant.
